R&D As an enterprise with excellent abilities for independent research and development, NCPC was the first in China to succeed in developing dozen of new products: such as bacitracin, kasugamycin, bleomycin, amphotericin B, lindomycin, clindamycin, clindamycin phosphate and norvancomycin. NCPC New Drug R&D Co., Ltd. is responsible for the new drug and technology development of the whole NCPC Group. Nearly 300 talented experts and technicians, advanced instruments and integrated pilot unit make it possible to transform laboratory reactions into large-scale production. In recent 10 years, R&D investment of NCPC kept occupying over 30% of sales volume annually. Based on the long-term abundant input, NCPC has new products put into market every year. NCPC has been transferring from generic imitation into original research in new drug development and forming a development platform of its own. Its original research focuses on the natural and small molecular drugs screening, combinatorial chemical technology and modern biotechnology.

Address：388 Heping Donglu,Shijiazhuang,P.R.China
Postalcode：050015
Telephone：0311-85993618  85528566
Fax：0311-85051711
Email：daijing@ncpc.com